Targeting melanoma’s MCL1 bias unleashes the apoptotic potential of BRAF and ERK1/2 pathway inhibitors

BRAF and MEK1/2 inhibitors are effective in melanoma but resistance inevitably develops. Despite increasing the abundance of pro-apoptotic BIM and BMF, ERK1/2 pathway inhibition is predominantly cytostatic, reflecting residual pro-survival BCL2 family activity. Here, we show that uniquely low BCL-X(...

Descripción completa

Detalles Bibliográficos
Autores principales: Sale, Matthew J., Minihane, Emma, Monks, Noel R., Gilley, Rebecca, Richards, Frances M., Schifferli, Kevin P., Andersen, Courtney L., Davies, Emma J., Vicente, Mario Aladren, Ozono, Eiko, Markovets, Aleksandra, Dry, Jonathan R., Drew, Lisa, Flemington, Vikki, Proia, Theresa, Jodrell, Duncan I., Smith, Paul D., Cook, Simon J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6856071/
https://www.ncbi.nlm.nih.gov/pubmed/31727888
http://dx.doi.org/10.1038/s41467-019-12409-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6856071/
https://www.ncbi.nlm.nih.gov/pubmed/31727888
http://dx.doi.org/10.1038/s41467-019-12409-w

Ejemplares similares